Calton & Associates Inc. Raises Holdings in Johnson & Johnson $JNJ

Key Points

• Calton & Associates Inc. increased its stake in Johnson & Johnson by 59.9% in the 1st quarter, acquiring an additional 2,074 shares, bringing its total holdings to 5,539 shares worth $919,000.
• Johnson & Johnson reported earnings per share (EPS) of $2.77 for the last quarter, exceeding analysts' expectations of $2.68, with a revenue of $23.74 billion compared to the expected $22.85 billion.
• The company recently announced a quarterly dividend of $1.30 per share, translating to an annualized dividend of $5.20 and a yield of 2.9%.

Calton & Associates Inc. increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 59.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,539 shares of the company's stock after purchasing an additional 2,074 shares during the quarter. Calton & Associates Inc.'s holdings in Johnson & Johnson were worth $919,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Saudi Central Bank acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $157,000. Lanham O Dell & Company Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $213,000. Second Line Capital LLC increased its holdings in shares of Johnson & Johnson by 7.8% during the 1st quarter. Second Line Capital LLC now owns 5,753 shares of the company's stock worth $954,000 after acquiring an additional 417 shares during the last quarter. Centric Wealth Management increased its holdings in shares of Johnson & Johnson by 436.7% during the 1st quarter. Centric Wealth Management now owns 18,461 shares of the company's stock worth $3,062,000 after acquiring an additional 15,021 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 4.2% during the 1st quarter. Baird Financial Group Inc. now owns 4,094,430 shares of the company's stock worth $679,020,000 after acquiring an additional 164,106 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ stock traded down $0.35 during midday trading on Wednesday, hitting $177.71. The company's stock had a trading volume of 6,831,999 shares, compared to its average volume of 8,970,411. The stock's 50-day moving average price is $167.02 and its 200 day moving average price is $160.33. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The stock has a market cap of $427.98 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.During the same period in the previous year, the company posted $2.82 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Guggenheim reissued a "neutral" rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.